Hanmi Unveils Novel Obesity Drug 'HM17321' : A Game-Changer in Overcoming GLP-1-Associated Muscle Loss

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Hanmi-Pharmaceutical

More Like This

PR Newswire associated0

Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy

PR Newswire associated0

Hanmi Signs Licensing Deal with Lilly for sonefpeglutide (LAPSGLP-2 analog)

HUADONG MEDICINE Announces Positive Phase I Results for Innovative Oral Small Molecule GLP-1 Receptor Agonist HDM1002

PR Newswire associated0

Gan & Lee Pharmaceuticals Announces Significant Progress on New Diabetes and Obesity Treatments at the American Diabetes Association's 84th Scientific Sessions

MRI-based muscle assessment - Determining the relationship between drug-induced weight reduction and muscle health (Photo: Business Wire)

Adapting To Change: New Focused Review in Circulation Explores The Relationship Between Weight Reduction and Muscle Health

PR Newswire associated0

Daewoong Pharmaceutical to Initiate Clinical Trials Early Next Year for Innovative 'GLP-1 Obesity Treatment' with Advanced Microneedle Technology for Sustained Weekly Efficacy

PR Newswire associated0

Gan & Lee Pharmaceuticals Announced First Participant Dosed in the US Phase 2 Clinical Study of Bofanglutide (GZR18) Injection for Overweight or Obesity

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog at American Diabetes Association's 85th Scientific Sessions